Project Details
Description
PROJECT SUMMARY/ABSTRACT
In this proposal, we will leverage our laboratory’s extensive expertise and experience in National Institutes of
Health (NIH) observational studies and provide kit management, specimen management, study management,
routine diagnostic testing, and specialty renal biomarker testing for the Chronic Kidney Disease in Children
(CKiD) study. The University of Minnesota’s Advanced Research and Diagnostic Laboratory (ARDL) has
become a trusted resource for clinical trial testing. Here we emphasize our ability to perform accurate and
precise iohexol measurements using liquid chromatography tandem mass spectrometry (LC-MS/MS) to allow
for gold standard measured glomerular filtration rate (mGFR) determinations in CKiD subjects. This and
routine diagnostic testing is instrumental in understanding the relationships of chronic kidney disease (CKD) to
neurocognitive development, behavior development, social development, and cardiovascular disease risk.
CKiD investigators previously developed the CKiD under 25 (U25) equation to estimate GFR (eGFR) since
adult eGFR equations do not perform well in this young demographic. Our specific aims are (Aim 1) to analyze
specimens undergoing the CKiD iohexol mGFR protocol for adolescents in the 14-17 years of age via new
recruitment to better validate and possibly improve upon the U25 eGFR equation accuracy. We are
approaching this with the hypothesis that when incorporating a larger pediatric population with mGFR results
into the U25 eGFR equation, specifically in the emerging adult population where data is sparse, the accuracy
of the U25 eGFR equation will be tested, validated, and potentially improved should the U25 equation model
need adjustment. Aim 2 involves acquiring mGFR results and specimens from a healthy young adult kidney
donor population at M Health Fairview to evaluate the U25 equation. Our hypothesis is since the current U25
equation was primarily generated from a CKD pediatric population, by evaluating young healthy patients with
this equation, the study will examine U25 equation continuity in all patients or it will assist in formulating a new
model that provides a better estimate of GFR in healthy and diseased pediatric populations. Lastly, Aim 3 sets
out to analyze routine and novel biomarkers to assess clinical interpretation and their relation to eGFR,
cardiovascular risk, social/behavioral development, and CKD progression. Our hypothesis is that biomarkers
such as creatinine and cystatin C will be input into the U25 equation and the results will allow for following CKD
progression. Biomarkers T50 and FGF23 will assist investigators in evaluating cardiovascular health in
subjects ≥14 years old with CKD at stages 4-5
Status | Active |
---|---|
Effective start/end date | 9/15/23 → 7/31/24 |
Funding
- National Institute of Diabetes and Digestive and Kidney Diseases: $323,467.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.